This study is currently not recruiting participants.

TN-19 Antithymocyte Globulin (ATG) and pegylated granulocyte colony stimulating factor (GCSF) in New Onset Type 1 Diabetes

Investigating Treatments for Type 1 Diabetes

Not Recruiting
12 years - 46 years
All
Phase N/A

Brief description of study.

The purpose of this study is to learn if either one of these treatments could also help people with newly diagnosed type 1 diabetes by delaying or stopping further destruction of beta cells.

Detailed description of study

The purpose of this study is to determine the safety and ability of lose dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: type 1 diabetes
  • Age: 12 years - 46 years
  • Gender: All

This study investigates treatments for people with newly diagnosed type 1 diabetes, a condition where the body's immune system attacks insulin-producing beta cells in the pancreas. The study aims to find out if two treatments can delay or stop this process.

Participants will receive either a combination of low dose ATG and GCSF or low dose ATG alone to see if these treatments can help maintain or improve C-peptide production. C-peptide is a protein that shows how much insulin the body is making.

  • Who can participate: Participants aged 18 to 45 years with a diagnosis of type 1 diabetes within the past 6 months are eligible. Key eligibility factors include no prior immunosuppressive therapy and adequate renal function.
  • Study details: Participants will receive either a low dose of ATG combined with GCSF or a low dose of ATG alone. A placebo is not used in this study.
Updated on 19 Feb 2024. Study ID: 1408829461

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team